HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JDQ443

Also Known As:

1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl)-2-azaspiro(3.3)heptan-2-yl)prop-2-en-1-one

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - JDQ443: 3

Experts

1.	Barys, Louise: 1 article (01/2022)
2.	Beyer, Kim S: 1 article (01/2022)
3.	Bomio-Confaglia, Claudio: 1 article (01/2022)
4.	Brachmann, Saskia M: 1 article (01/2022)
5.	Burks, Heather: 1 article (01/2022)
6.	Chen, Xueying: 1 article (01/2022)
7.	Cotesta, Simona: 1 article (01/2022)
8.	Cui, Xiaoming: 1 article (01/2022)
9.	Dharmarajan, Lekshmi: 1 article (01/2022)
10.	Farago, Anna F: 1 article (01/2022)

Related Diseases

1.

Neoplasms (Cancer)

11/07/2023 - "Tumor regression by single-agent JDQ443 at clinically relevant doses lasted on average 2 weeks and was increasingly extended by the double, triple or quadruple combinations. "
01/01/2022 - "In preclinical models and patients with KRASG12C-mutated malignancies, JDQ443 shows potent antitumor activity as monotherapy and in combination with the SHP2 inhibitor TNO155. "
01/01/2022 - "JDQ443 is in clinical development as monotherapy and in combination with TNO155, with both strategies showing antitumor activity in patients with KRASG12C-mutated tumors. "
01/01/2022 - "In vivo, JDQ443 induces AUC exposure-driven antitumor efficacy in KRASG12C-mutated cell-derived (CDX) and patient-derived (PDX) tumor xenografts. "
12/22/2022 - "JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors."

Related Drugs and Biologics

1.	Alpelisib
2.	pyrazole
3.	ribociclib